WHO chief declares end to COVID-19 as a global health emergency
The head of the UN World Health Organization (WHO) has declared “with great hope” an end to COVID-19 as a public health emergency, stressing that it does not mean the disease is no longer a global threat.
World Health Organization declares the coronavirus outbreak a global pandemic
Guidance for the Proper Selection and Use of Personal Protective Equipment (PPE) in Healthcare Settings March - 2020
Guidance for the Proper Selection and Use of Personal Protective Equipment (PPE) in Healthcare Settings March - 2020
General Directorate of Infection Prevention and Control (GDIPC)
Key Findings From the Chinese Center for Disease Control and Prevention Report
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
72 314 Cases (as of February 11, 2020)
-
-
Confirmed cases: 44 672 (62%)
-
Suspected cases: 16 186 (22%)
-
Diagnosed cases: 10 567 (15%)
-
Asymptomatic cases: 889 (1%)
-
-
Age distribution (N = 44 672)
-
≥80 years: 3% (1408 cases)
-
30-79 years: 87% (38 680 cases)
-
20-29 years: 8% (3619 cases)
-
10-19 years: 1% (549 cases)
-
<10 years: 1% (416 cases)
-
-
Spectrum of disease (N = 44 415)
-
Mild: 81% (36 160 cases)
-
Severe: 14% (6168 cases)
-
Critical: 5% (2087 cases)
-
-
Case-fatality rate
-
2.3% (1023 of 44 672 confirmed cases)
-
14.8% in patients aged ≥80 years (208 of 1408)
-
8.0% in patients aged 70-79 years (312 of 3918)
-
49.0% in critical cases (1023 of 2087)
-
-
Health care personnel infected
-
3.8% (1716 of 44 672)
-
63% in Wuhan (1080 of 1716)
-
14.8% cases classified as severe or critical (247 of 1668)
-
5 deaths
-
Coronavirus Disease 19 (COVID-19) Guidelines February 2020 V1.1
Coronavirus Disease 19 (COVID-19) Guidelines February 2020 V1.1
Version 1.0 was written and published on January 10th 2020.
Version 1.1
- Updated the name of the virus and the disease name.
- Updated the case definition
- Added (Management of exposure to COVID-19 in healthcare facilities)
- Added (The risk communication)
- Updated the designated hospitals list
- Updated the reporting form and the visual triage checklist form.
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
Abstract
The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.